The emergence of multidrug resistant bacteria has prioritized the development of new antibiotics. N-substituted pantothenamides, analogs of the natural compound pantetheine, were reported to target bacterial coenzyme A biosynthesis, but these compounds have never reached the clinic due to their instability in biological fluids. Plasma-stable pantothenamide analogs could overcome these issues. We first synthesized a number of bioisosteres of the prototypic pantothenamide N7-Pan. A compound with an inverted amide bond (CXP18.6-012) was found to provide plasma-stability with minimal loss of activity compared to the parent compound N7-Pan. Next, we synthesized inverted pantothenamides with a large variety of side chains. Among these we identified a number of novel stable inverted pantothenamides with selective activity against Gram-positive bacteria such as staphylococci and streptococci, at low micromolar concentrations. These data provide future direction for the development of pantothenamides with clinical potential.
多药耐药细菌的出现使得新抗生素的开发变得尤为重要。N取代的泛酰胺作为天然化合物泛酰胺的类似物,已被报道能靶向细菌
辅酶A的
生物合成,但由于在
生物液体中不稳定,这些化合物从未进入临床。稳定的泛酰胺类似物可以克服这些问题。我们首先合成了多种原型泛酰胺N7-Pan的
生物等排体。发现一种反向酰胺键的化合物(CXP18.6-012)在与母体化合物N7-Pan相比时,能够提供血浆稳定性且活性损失最小。接下来,我们合成了具有多种侧链的反向泛酰胺。在这些化合物中,我们识别出了一些新型的稳定反向泛酰胺,其对革兰氏阳性细菌如
金黄色葡萄球菌和链球菌表现出选择性活性,浓度在低微摩尔范围。这些数据为未来具有临床潜力的泛酰胺的开发提供了方向。